March 28 (Reuters) - pSivida Corp:
* PSIVIDA CORP ANNOUNCES TRANSFORMATIVE ACQUISITION OF ICON BIOSCIENCE INC AND GROWTH CAPITAL FINANCING WITH ESSEX WOODLANDS HEALTHCARE PARTNERS – COMPANY WILL REBRAND AS EYEPOINT PHARMACEUTICALS INC
* PSIVIDA CORP - SWK HOLDINGS WILL PROVIDE UP TO $20 MILLION IN DEBT FINANCING
* PSIVIDA CORP - DEAL FOR APPROXIMATELY $60.5 MILLION
* PSIVIDA CORP - PSIVIDA CORP. WILL REBRAND AND CHANGE ITS NAME TO EYEPOINT PHARMACEUTICALS INC.
* PSIVIDA CORP - ENTERED INTO A FINANCIAL AGREEMENT WITH EW HEALTHCARE PARTNERS
* PSIVIDA CORP - EW HEALTHCARE PARTNERS AND A THIRD PARTY INVESTOR WILL MAKE EQUITY INVESTMENTS IN PSIVIDA
* PSIVIDA CORP - WILL USE FUNDS TO FINANCE ICON ACQUISITION AND PREPARE FOR COMMERCIAL LAUNCHES OF DEXYCU
* PSIVIDA CORP - IF APPROVED, PSIVIDA EXPECTS TO LAUNCH DURASERT IN U.S. IN FIRST HALF OF 2019
* PSIVIDA CORP - PSIVIDA PLANS TO LAUNCH DEXYCU IN U.S. IN FIRST HALF OF 2019
* PSIVIDA CORP - EW HEALTHCARE PARTNERS AND A THIRD PARTY INVESTOR WILL MAKE AN EQUITY INVESTMENT IN PSIVIDA FOR UP TO ABOUT $60.5 MILLION Source text for Eikon: Further company coverage:
